JP2015515984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515984A5 JP2015515984A5 JP2015510364A JP2015510364A JP2015515984A5 JP 2015515984 A5 JP2015515984 A5 JP 2015515984A5 JP 2015510364 A JP2015510364 A JP 2015510364A JP 2015510364 A JP2015510364 A JP 2015510364A JP 2015515984 A5 JP2015515984 A5 JP 2015515984A5
- Authority
- JP
- Japan
- Prior art keywords
- bromocriptine
- bromocriptine mesylate
- tablet
- mesylate
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 141
- 229960002802 bromocriptine Drugs 0.000 claims 141
- 239000003826 tablet Substances 0.000 claims 58
- 239000000203 mixture Substances 0.000 claims 49
- 238000009472 formulation Methods 0.000 claims 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 36
- 239000007935 oral tablet Substances 0.000 claims 32
- 229940096978 oral tablet Drugs 0.000 claims 31
- 239000002245 particle Substances 0.000 claims 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims 19
- 238000004090 dissolution Methods 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 238000009826 distribution Methods 0.000 claims 17
- 210000001156 gastric mucosa Anatomy 0.000 claims 11
- 210000004347 intestinal mucosa Anatomy 0.000 claims 11
- 230000002641 glycemic effect Effects 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 235000020937 fasting conditions Nutrition 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/460,452 US8431155B1 (en) | 2012-04-30 | 2012-04-30 | Bromocriptine formulations |
| US13/460,452 | 2012-04-30 | ||
| PCT/US2013/038655 WO2013165902A1 (en) | 2012-04-30 | 2013-04-29 | Bromocriptine formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515984A JP2015515984A (ja) | 2015-06-04 |
| JP2015515984A5 true JP2015515984A5 (https=) | 2016-06-30 |
| JP6180515B2 JP6180515B2 (ja) | 2017-08-16 |
Family
ID=48146046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510364A Active JP6180515B2 (ja) | 2012-04-30 | 2013-04-29 | ブロモクリプチン製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (11) | US8431155B1 (https=) |
| EP (4) | EP2844229B1 (https=) |
| JP (1) | JP6180515B2 (https=) |
| KR (1) | KR101593360B1 (https=) |
| AR (1) | AR091351A1 (https=) |
| AU (3) | AU2013256558B2 (https=) |
| BR (1) | BR112014027087B1 (https=) |
| CA (1) | CA2872300C (https=) |
| ES (4) | ES3050125T3 (https=) |
| MX (2) | MX363670B (https=) |
| UY (1) | UY34776A (https=) |
| WO (1) | WO2013165902A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| ES2763873T3 (es) | 2007-06-21 | 2020-06-01 | Veroscience Llc | Método de tratamiento de trastornos metabólicos y depresión con agonistas del receptor de dopamina |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| NZ630040A (en) | 2012-05-03 | 2016-10-28 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| WO2017184875A1 (en) | 2016-04-20 | 2017-10-26 | Veroscience Llc | Composition and method for treating metabolic disorders |
| US10426772B2 (en) | 2016-05-16 | 2019-10-01 | Regents Of The University Of Minnesota | Use of ergot alkaloids as an anthelmintic agent |
| HRP20241365T1 (hr) | 2017-10-18 | 2024-12-20 | Veroscience Llc | Poboljšane formulacije bromokriptina |
| CA3149877A1 (en) | 2019-09-23 | 2021-04-01 | Anthony H. Cincotta | Method for inducing tumor regression |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783469A (en) | 1986-03-07 | 1988-11-08 | Meier Albert H | Method of inhibiting body fat stores |
| US4659715A (en) | 1986-03-07 | 1987-04-21 | Louisiana State University And Agricultural And Mechanical College | Method of inhibiting body fat stores |
| US4791125A (en) | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
| US5700800A (en) | 1988-05-10 | 1997-12-23 | Ergo Science Incorporated | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound |
| US5830895A (en) | 1988-05-10 | 1998-11-03 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for the determination and adjustment of prolactin daily rhythms |
| US5716933A (en) | 1988-05-10 | 1998-02-10 | Louisiana State University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates |
| US6004972A (en) | 1988-05-10 | 1999-12-21 | The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5668155A (en) | 1988-05-10 | 1997-09-16 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| US5744477A (en) | 1988-05-10 | 1998-04-28 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for treatment of obesity using prolactin modulators and diet |
| US5344832A (en) | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5468755A (en) | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US5585347A (en) | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
| US5006526A (en) | 1988-10-17 | 1991-04-09 | Louisiana State University | Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis |
| IT1235053B (it) * | 1989-04-07 | 1992-06-17 | Poli Ind Chimica Spa | Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti. |
| CA2030174C (en) | 1990-01-10 | 1996-12-24 | Anthony H. Cincotta | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates |
| US5696128A (en) | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| IL112106A0 (en) * | 1993-12-22 | 1995-03-15 | Ergo Science Inc | Accelerated release composition containing bromocriptine |
| GB9421836D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
| US5565454A (en) | 1995-05-31 | 1996-10-15 | Ergo Science, Incorporated | Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions |
| US5626860A (en) | 1995-06-07 | 1997-05-06 | The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College | Method for regulating metabolism with dopamine beta hydroxylase inhibitors |
| US5714519A (en) | 1995-06-07 | 1998-02-03 | Ergo Science Incorporated | Method for regulating glucose metabolism |
| US5792748A (en) | 1995-06-07 | 1998-08-11 | The General Hospital Corporation | Method for inhibiting neoplastic disease in mammals |
| US20010016582A1 (en) | 1997-04-28 | 2001-08-23 | Anthony H. Cincotta | Method and composition for the treatment of lipid and glucose metabolism disorders |
| US5877183A (en) | 1996-06-06 | 1999-03-02 | Ergo Research Corporation | Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists |
| US20040077679A1 (en) | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20050054652A1 (en) | 2002-07-29 | 2005-03-10 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20040220190A1 (en) | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20040081678A1 (en) | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| HUE036646T2 (hu) | 2003-01-23 | 2018-07-30 | Esperion Therapeutics Inc | Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US8137993B2 (en) | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US20050215558A1 (en) | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
| US8137994B2 (en) | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| ATE430559T1 (de) | 2005-03-04 | 2009-05-15 | Nycomed Pharma As | Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett |
| EP2404604B1 (en) * | 2006-01-05 | 2019-02-06 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
| JP5215172B2 (ja) * | 2006-04-13 | 2013-06-19 | 東亜薬品株式会社 | 乾式直打速崩壊性錠剤 |
| JP5612462B2 (ja) * | 2007-04-13 | 2014-10-22 | ダウ グローバル テクノロジーズ エルエルシー | 剤形用の粒状物質 |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| US20210401824A1 (en) | 2007-06-21 | 2021-12-30 | Veroscience Llc | Parenteral Formulations of Dopamine Agonists |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| ES2763873T3 (es) | 2007-06-21 | 2020-06-01 | Veroscience Llc | Método de tratamiento de trastornos metabólicos y depresión con agonistas del receptor de dopamina |
| US7631155B1 (en) | 2007-06-30 | 2009-12-08 | Emc Corporation | Thin provisioning of a file system and an iSCSI LUN through a common mechanism |
| JP2011500557A (ja) * | 2007-10-11 | 2011-01-06 | マゼンス インコーポレイテッド | ナフトキノン系化合物の微粒化粒子を含有する医薬組成物 |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| EP2437732B1 (en) * | 2009-06-05 | 2018-05-09 | VeroScience LLC | Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders |
| CN103025332A (zh) | 2010-06-08 | 2013-04-03 | Vero科学有限责任公司 | 治疗代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗剂 |
| US20140051685A1 (en) | 2010-11-23 | 2014-02-20 | Anthony H. Cincotta | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| EP3008167A4 (en) | 2013-06-13 | 2017-06-07 | VeroScience LLC | Compositions and methods for treating metabolic disorders |
| WO2017184875A1 (en) | 2016-04-20 | 2017-10-26 | Veroscience Llc | Composition and method for treating metabolic disorders |
| US20170340271A1 (en) | 2016-05-26 | 2017-11-30 | Veroscience Llc | Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions |
| HRP20241365T1 (hr) | 2017-10-18 | 2024-12-20 | Veroscience Llc | Poboljšane formulacije bromokriptina |
| CA3149877A1 (en) | 2019-09-23 | 2021-04-01 | Anthony H. Cincotta | Method for inducing tumor regression |
-
2012
- 2012-04-30 US US13/460,452 patent/US8431155B1/en active Active
-
2013
- 2013-02-21 US US13/773,500 patent/US8613947B2/en active Active
- 2013-04-29 EP EP13721874.9A patent/EP2844229B1/en active Active
- 2013-04-29 EP EP21203207.2A patent/EP3960160B1/en active Active
- 2013-04-29 MX MX2014013158A patent/MX363670B/es unknown
- 2013-04-29 CA CA2872300A patent/CA2872300C/en active Active
- 2013-04-29 JP JP2015510364A patent/JP6180515B2/ja active Active
- 2013-04-29 ES ES23214280T patent/ES3050125T3/es active Active
- 2013-04-29 ES ES13721874T patent/ES2755081T3/es active Active
- 2013-04-29 WO PCT/US2013/038655 patent/WO2013165902A1/en not_active Ceased
- 2013-04-29 KR KR1020147033501A patent/KR101593360B1/ko active Active
- 2013-04-29 ES ES19191600T patent/ES2902573T3/es active Active
- 2013-04-29 AU AU2013256558A patent/AU2013256558B2/en not_active Ceased
- 2013-04-29 EP EP23214280.2A patent/EP4342536B1/en active Active
- 2013-04-29 EP EP19191600.6A patent/EP3620155B1/en not_active Not-in-force
- 2013-04-29 ES ES21203207T patent/ES2972198T3/es active Active
- 2013-04-29 BR BR112014027087-2A patent/BR112014027087B1/pt not_active IP Right Cessation
- 2013-04-30 AR ARP130101471 patent/AR091351A1/es unknown
- 2013-04-30 UY UY0001034776A patent/UY34776A/es not_active Application Discontinuation
- 2013-11-22 US US14/088,269 patent/US9192576B2/en active Active
-
2014
- 2014-10-29 MX MX2019003619A patent/MX2019003619A/es unknown
-
2015
- 2015-10-22 US US14/920,123 patent/US9522117B2/en active Active
-
2016
- 2016-04-22 AU AU2016202572A patent/AU2016202572B2/en not_active Ceased
- 2016-10-06 US US15/286,826 patent/US9700555B2/en active Active
-
2017
- 2017-06-08 US US15/618,055 patent/US9993474B2/en active Active
-
2018
- 2018-05-01 AU AU2018203021A patent/AU2018203021B2/en not_active Ceased
- 2018-05-16 US US15/981,752 patent/US10307421B2/en active Active
-
2019
- 2019-04-24 US US16/393,463 patent/US10688094B2/en active Active
-
2020
- 2020-05-19 US US16/878,451 patent/US11000522B2/en active Active
-
2021
- 2021-04-09 US US17/227,089 patent/US11666567B2/en active Active
-
2023
- 2023-04-26 US US18/307,435 patent/US20240131026A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515984A5 (https=) | ||
| JP6141583B2 (ja) | 濫用耐性製剤 | |
| KR102644781B1 (ko) | 코티코트로핀 방출 인자 수용체 길항제 | |
| JP2014528474A5 (https=) | ||
| JP2009215293A5 (https=) | ||
| RU2010141333A (ru) | Новая доза и препаративная форма | |
| CN104306329A (zh) | 一种盐酸溴己新注射液及其制备方法和用途 | |
| TW202539655A (zh) | Glp-1受體非肽促效劑化合物之口服投藥 | |
| JP2016512247A5 (https=) | ||
| JP2015515974A5 (https=) | ||
| CN106511312A (zh) | 一种复方西地那非达泊西汀缓释胶囊及其制备方法 | |
| CN104706604A (zh) | 一种吡仑帕奈冻干口崩片及其制备方法 | |
| JP5347092B2 (ja) | アンドログラフィス抽出物製剤 | |
| JP6060176B2 (ja) | 憩室症の治療のための方法及び組成物 | |
| CN107205943A (zh) | 纳洛酮单剂和多层片剂 | |
| CN1739513A (zh) | 一种氯雷他定口腔崩解片剂及其制备方法 | |
| US20210361673A1 (en) | Compositions and methods of treating viral infections | |
| CN104936585B (zh) | 包括苯肾上腺素和扑热息痛的组合药剂 | |
| CN104224728A (zh) | 一种埃索美拉唑肠溶微丸及其制备方法 | |
| CN105878200A (zh) | 一种盐酸曲美他嗪缓释片及其制备方法 | |
| CN108434110B (zh) | 米索前列醇组合物、片剂及其用途 | |
| CN115089618A (zh) | 一种用于防治骨质疏松的药物组合物及其制备方法 | |
| ES2703376T3 (es) | Preparación de combinación farmacéutica de inhibidor de ACE y diurético de bucle | |
| CN107252418B (zh) | 一种3d打印技术制备治疗低钾血症的口腔速崩片的方法 | |
| WO2011100668A4 (en) | Methods and compositions of civamide to treat diseases of the intestines |